RESUMO
Leptin is a new plausible candidate for the molecular link between nutritional status and the reproductive axis. In previous studies we described that continuous natural nematode infections in heifers retarded growth and delayed the onset of puberty, and that the insulin-like growth factor I (IGF-I) was involved. In the present study we monitored the leptin levels during development in heifers naturally parasitized versus those chronically treated with ivermectin and we investigated whether growth hormone (GH) accounted for the differences in IGF-I previously noted. Insulin levels were also measured. Prolactin hormone was recorded as an indicator of immune system activation. We found a direct correlation between leptin and body weight during development and a prepubertal surge of the hormone 2 weeks before the first progesterone peak that indicates the onset of puberty. This suggests that leptin may act as a signal for this event. Insulin did not vary during growth and prepuberty. On the other hand, GH as not responsible for diminished IGF-I levels in parasitized animals as levels were similar in both groups. The GH levels were high at birth and then diminished rapidly and remained constant during development and puberty. The last hormone studied, prolactin, followed seasonal changes of sunlight duration and presented sporadic bursts in infected animals. These were related to high nematode infection and are probably involved in the immune response of the host.
Assuntos
Doenças dos Bovinos/fisiopatologia , Bovinos/fisiologia , Leptina/biossíntese , Infecções por Nematoides/veterinária , Maturidade Sexual/fisiologia , Animais , Antinematódeos/administração & dosagem , Peso Corporal , Bovinos/metabolismo , Bovinos/parasitologia , Doenças dos Bovinos/metabolismo , Fezes/parasitologia , Feminino , Hormônio do Crescimento/sangue , Insulina/sangue , Fator de Crescimento Insulin-Like I/metabolismo , Ivermectina/administração & dosagem , Leptina/sangue , Nematoides/crescimento & desenvolvimento , Infecções por Nematoides/metabolismo , Contagem de Ovos de Parasitas/veterinária , Progesterona/sangue , Prolactina/sangueRESUMO
Continuous treatment with ivermectin from birth to puberty advanced sexual maturation by 3.7 wk in Holstein heifers grazing pastures naturally infected with nematodes. Every 14 d jugular blood samples were taken from birth to 45 wk of age from all heifers. No differences in serum FSH, estradiol, or thyroxine levels were observed during the trial between the treated and untreated group. Mean LH levels were diminished in untreated heifers 4 wk before the first estrus and the amplitude of LH pulses was augmented in treated heifers when puberty was reached. Serum IGF-I levels increased from birth to 22 wk of age and then reached a plateau in both groups, but levels were consistently higher in treated heifers from 26 wk of age onward. Body weight gain was retarded in parasitized heifers and IGF-I values were positively correlated with body weight only during the first 20 wk of life. We suggest that enhanced prepubertal IGF-I levels in conjunction with increased prepubertal LH levels and pubertal LH pulse amplitude might be involved in the accelerated somatic maturation and in puberty advancement observed in ivermectin-treated heifers.
Assuntos
Antinematódeos/farmacologia , Bovinos/crescimento & desenvolvimento , Ivermectina/farmacologia , Maturidade Sexual/efeitos dos fármacos , Animais , Indústria de Laticínios , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Fator de Crescimento Insulin-Like I/metabolismo , Hormônio Luteinizante/sangue , Contagem de Ovos de Parasitas/veterinária , Progesterona/sangue , Radioimunoensaio/veterinária , Tiroxina/sangue , Aumento de PesoRESUMO
The effect of continuous ivermectin treatment from birth to puberty on growth and reproductive performance was studied in Holstein heifer calves grown on pastures in comparison to naturally nematode-infected, untreated animals. Ivermectin effectively abated the presence of nematode eggs in feces. Eggs per gram (EPG) in parasitized animals increased rapidly from wk 12 to 18 of age and then decreased. Animals treated with ivermectin grew faster than untreated ones, and differences in body weight became significant at 6 wk of life, even before eggs appeared in the feces of either treatment group. Ivermectin-treated heifers reached puberty 3 wk earlier than infected ones as assessed with serum progesterone concentrations (ivermectin, 30.4 +/- .8 vs untreated, 33.7 +/- 1.3 wk of age). This delay was not directly related to body weight. In addition, pelvic area at 39 wk and at 15 mo of age was increased in treated heifers (8 and 11%, respectively) compared with parasitized animals. No differences in the wither heights were observed. We conclude that ivermectin treatment in dairy heifers may increase growth rate during development, advance the onset of ovarian function, and positively affect yearling pelvic area.
Assuntos
Anti-Helmínticos/uso terapêutico , Bovinos/crescimento & desenvolvimento , Indústria de Laticínios/métodos , Ivermectina/uso terapêutico , Animais , Anti-Helmínticos/administração & dosagem , Bovinos/parasitologia , Doenças dos Bovinos/parasitologia , Doenças dos Bovinos/prevenção & controle , Fezes/parasitologia , Feminino , Ivermectina/administração & dosagem , Masculino , Infecções por Nematoides/parasitologia , Infecções por Nematoides/prevenção & controle , Contagem de Ovos de Parasitas/veterinária , Estações do Ano , Maturidade Sexual/efeitos dos fármacosRESUMO
We have used the nonpeptide angiotensin II (ANG II) receptor antagonists losartan (receptor subtype AT1) and PD-123319 (AT2) to determine the participation of ANG II receptor subtypes in luteinizing hormone-releasing hormone (LHRH)-induced prolactin release in a perifusion study using intact pituitaries in vitro. LHRH (1.85 x 10(-7) M) released prolactin consistently, whereas losartan (10(-5) M) abolished prolactin response without modifying basal prolactin or luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. PD-123319 (10(-5) M) had no effect on basal or LHRH-induced prolactin, LH, or FSH release. We also determined that the effect of ANG II on prolactin release was mediated by the same receptor subtype. In adenohypophysial cells dispersed in vitro ANG II (10(-8) M) released prolactin. Losartan (10(-7) and 10(-6) M), but not PD-123319, inhibited this effect. We conclude that in intact hypophyses of 15-day-old female rats the effect of LHRH on prolactin release is readily demonstrated. LHRH-induced prolactin release appears to be mediated by ANG II acting in a paracrine manner on AT1 receptors located on lactotrophs.
Assuntos
Angiotensina II/farmacologia , Hormônio Liberador de Gonadotropina/farmacologia , Hipófise/metabolismo , Prolactina/metabolismo , Receptores de Angiotensina/fisiologia , Antagonistas de Receptores de Angiotensina , Animais , Compostos de Bifenilo/farmacologia , Feminino , Imidazóis/farmacologia , Técnicas In Vitro , Losartan , Perfusão/métodos , Hipófise/citologia , Piridinas/farmacologia , Ratos , Ratos Sprague-Dawley , Tetrazóis/farmacologiaRESUMO
The prolactin-releasing effect of angiotensin II (AII) was studied in the developing female and male rat in vivo and in vitro. AII (50 and 100 micrograms/100 g b.w.) was injected intraperitoneally to female and male rats aged 4, 12, 20 and 28 days and males aged 38 days. AII (10(-6) M) was also tested in pituitaries incubated in vitro from animals of both sexes aged 12, 20 and 28 days. In addition, as two subtypes of AII receptors have been characterized on the basis of displacement with specific AII antagonists, we used the nonpeptide AII receptor antagonists losartan (AT1 subtype) and PD 123319 (AT2 subtype) to determine the AII receptor subtype functionally involved in AII-induced prolactin secretion in vivo in 25-day-old male rats. The efficiency of the prolactin-releasing effect of AII in vivo increased with age, and first responses were observed at 20 days of age in both sexes. No sexual differences were encountered. On the other hand, AII-induced prolactin release from pituitaries incubated in vitro was first demonstrated at 12 days in females and at 20 days in males. The effect increased with age in both sexes, and, at 28 days, pituitaries from females released more prolactin in response to AII than those from males. Losartan (3 mg/kg) completely abolished AII (50 micrograms/100 g b.w.)-induced prolactin release in vivo, while PD 123319 (3 mg/kg) did not. This suggests that pituitary AT1 receptors are functionally involved in the prolactin release induced by AII in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Envelhecimento/metabolismo , Angiotensina II/farmacologia , Prolactina/metabolismo , Angiotensina II/antagonistas & inibidores , Antagonistas de Receptores de Angiotensina , Animais , Compostos de Bifenilo/farmacologia , Relação Dose-Resposta a Droga , Feminino , Imidazóis/farmacologia , Técnicas In Vitro , Losartan , Masculino , Hipófise/metabolismo , Piridinas/farmacologia , Ratos , Ratos Sprague-Dawley , Tetrazóis/farmacologia , Fatores de TempoRESUMO
1. Serum prolactin levels are low during the first 20 days of life and gradually increase toward puberty, in both male and female rats. 2. There is an age-related increase in the cell population engaged in prolactin secretion, as well as an increase in the synthesis of prolactin and of the amount of prolactin secreted from individual lactotropes. 3. The gradual increase in prolactin levels in the third week of life is not related to a decrease in dopaminergic inhibition but to an increase in the efficiency of prolactin releasing factors such as estrogen, serotonin, opiates, and posterior pituitary extracts. 4. Prolactin release induced by physiological factors, such as stress, cervical stimulation, or the expression of spontaneous diurnal and nocturnal surges, requires maturational events within the hypothalamic-pituitary axis which are evident at the end of the third week of life. 5. In the female rat the steadily increasing levels of prolactin are involved in the timing of puberty eclosion acting at the ovary and at the brain. 6. In the prepubertal male rat increasing titers of prolactin may be involved in testicular and accessory organ development and may facilitate the actions of luteinizing hormone, follicle stimulating hormone, and testosterone on male sexual organs.
Assuntos
Adeno-Hipófise/metabolismo , Prolactina/metabolismo , Fatores Etários , Animais , Dopamina/fisiologia , Feminino , Hormônios Esteroides Gonadais/fisiologia , Sistema Hipotálamo-Hipofisário/fisiologia , Masculino , Ovário/fisiologia , Periodicidade , Adeno-Hipófise/crescimento & desenvolvimento , Sistema Hipófise-Suprarrenal/fisiologia , Ratos , Serotonina/fisiologia , Fatores Sexuais , Maturidade Sexual , Testículo/fisiologiaRESUMO
The ontogeny of diazepam's endocrine effects in male and female rats, and of 3H-diazepam binding in the hypothalami of both sexes was studied. Diazepam inhibited basal prolactin levels in 38 day-old male rats and, if prolactin levels were stimulated by Haloperidol the inhibition occurred in 28 day-old males, indicating that the hypoprolactinemic effect of the drug could be evidenced earlier if prolactin titers were high. The prolactin inhibition in females did not reach statistical significance at any studied age. Diazepam significantly released LH only in male rats at 12 days, showing thus, a period of special sensitivity of LH release to the drug. Benzodiazepine-hypothalamic binding sites increased in number from birth to puberty, reaching a plateau at 20 days of age. No sexual differences or changes in affinity were found throughout the studied period. These results suggest that the maturation of diazepam's hypoprolactinemic effect could be partially related to the increase in hypothalamic binding sites, whereas the sexual differences observed in diazepam's endocrine actions could be due to sexual differentiation of endocrine control mechanisms.